Web1 day ago · Fusion Pharmaceuticals ( NASDAQ: FUSN) delivers an alpha emitting payload to cancer cells using its proprietary linker technology that uses IGF-1R, an established … WebApr 2, 2024 · By AuntMinnie.com staff writers April 2, 2024 -- Fusion Pharmaceuticals has acquired the intellectual property and assets related to French firm Ipsen's IPN-1087 radiopharmaceutical. The small molecule targets neurotensin receptor 1 (NTSR1) -- a protein expressed on multiple solid tumor types.
PETNET Solutions Inc. - Siemens Healthineers USA
WebMar 31, 2024 · Lantheus has a focus on diagnostics and therapeutics, the latter through a pair of PSMA-targeting prostate cancer projects, I-131-1095 and the Bayer-partnered BAY 2315497. These respectively use iodine-131 … WebIpsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on transformative medicines in three therapeutic areas: oncology, rare disease and neuroscience.Ipsen is one of the world’s top 15 biopharmaceutical companies in terms of oncology sales. Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 … impurity\\u0027s fd
Ipsen - Wikipedia
WebJun 23, 2024 · Fusion acquired [177 Lu]-IPN-1087 (IPN-1087), a lutetium-based beta-emitting radiopharmaceutical, from Ipsen in April 2024, and converted the compound to the alpha-emitting [225 Ac]-FPI-2059. In clinical studies, IPN-1087 showed promising early safety data and good uptake in multiple tumor types. In a head-to-head in vivo comparison of ... WebApr 1, 2024 · HAMILTON, ON and BOSTON, April 1, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as... WebAug 5, 2024 · Ipsen argues the court's consideration of its motion to dismiss is likely to result in dismissal of the entire case, and Cipla disputes Ipsen's position. (D.I. 19 at 8-10; D.I. 22 at 10-11) While the case would be “greatly simplified” if the motion to dismiss is granted, “little efficiency gain would be realized” if the motion is denied ... impurity\u0027s fg